Novel anti-myeloma agents and angiogenesis

References

• Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9: 653–660
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27–31
   PubMed Web of Science ®Google Scholar
• Bergers G, Benjamin L E. Tumourigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3: 401–410
   PubMed Web of Science ®Google Scholar
• Rajkumar S V, Kyle R A. Angiogenesis in multiple myeloma. Semin Oncol 2001; 28: 560–564
   PubMed Web of Science ®Google Scholar
• Rajkumar S V, Mesa R A, Fonseca R, Schroeder G, Plevac M F, Dispenzieri A, et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 2002; 8: 2210–2216
   PubMed Web of Science ®Google Scholar
• Sezer O, Niemoller K, Kaufmann O, Eucker J, Jakob C, Zavrski I, et al. Decrease of bone marrow angiogenesis in myeloma patients achieving a remission after chemotherapy. Eur J Haematol 2001; 66: 238–244
   PubMed Web of Science ®Google Scholar
• Rajkumar S V, Leong T, Roche P C, Fonseca R, Dispenzieri A, Lacy M Q, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 2000; 6: 3111–3116
   PubMed Web of Science ®Google Scholar
• Sezer O, Niemöller K, Eucker J, Jakob C, Kaufmann O, Zavrski I, et al. Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Ann Hematol 2000; 79: 574–577
   PubMed Web of Science ®Google Scholar
• Pruneri G, Ponzoni M, Ferreri A J, Decarli N, Tresoldi M, Raggi F, et al. Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. Br J Haematol 2002; 118: 817–820
   PubMed Web of Science ®Google Scholar
• Sezer O, Niemoller K, Jakob C, Zavrski I, Heider U, Eucker J, et al. Relationship between bone marrow angiogenesis and plasma cell infiltration and serum b2-microglobulin levels in patients with multiple myeloma. Ann Hematol 2001; 80: 598–601
   PubMed Web of Science ®Google Scholar
• Niemöller K, Jakob C, Heider U, Zavrski I, Eucker J, Kaufmann O, et al. Bone marrow angiogenesis and its correlation with other disease characteristics in multiple myeloma in stage I versus stage II-III. J Cancer Res Clin Oncol 2003; 129: 234–238
   PubMed Web of Science ®Google Scholar
• Jacob C, Sterz J, Zavrski I, Heider U, Kleeberg L, Fleissner C, et al. Angiogenesis in multiple myeloma. Eur J Cancer 2006; 42: 1581–1590
   PubMed Web of Science ®Google Scholar
• Klein B, Zhang X G, Lu Z Y, Bataille R. Interleukin-6 in human multiple myeloma. Blood 1995; 85: 863–872
   PubMed Web of Science ®Google Scholar
• Motro B, Itin A, Sachs L, Keshet E. Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis. Proc Natl Acad Sci USA 1989; 87: 3092–3096
   Web of Science ®Google Scholar
• Dankbar B, Padro T, Leo R, Feldmann B, Kropff M, Mesters R M, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000; 95: 2630–2636
   PubMed Web of Science ®Google Scholar
• Houck K A, Ferrara N, Winer J, Cachianes G, Li B, Leung D W. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 1991; 5: 1806–1814
   PubMed Web of Science ®Google Scholar
• Fong G H, Rossant J, Gertsenstein M, Breitman M L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995; 376: 66–70
   PubMed Web of Science ®Google Scholar
• Shalaby F, Rossant J, Yamaguchi T P, Gertsenstein M, Wu X F, Breitman M L, et al. Failure of blood-island formation and vasculogenesis in Flk-1 – deficient mice. Nature 1995; 376: 62–66
   PubMed Web of Science ®Google Scholar
• Kumar S, Witzig T E, Timm M, Haug J, Wellik L, Fonseca R, et al. Expression of VEGF and its receptors by myeloma cells. Leukemia 2003; 17: 2025–2031
   PubMed Web of Science ®Google Scholar
• Podar K, Tai Y T, Davies F E, Lentzsh S, Sattler M, Hideshima T, et al. Vascular endothelial growth factor triggers signalling cascades mediating multiple myeloma cell growth and migration. Blood 2001; 98: 428–435
   PubMed Web of Science ®Google Scholar
• Davis S, Aldrich T H, Jones P F, Acheson A, Compton D L, Jain V, et al. Isolation of angiopoietin-1, a ligant for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996; 87: 1161–1169
   PubMed Web of Science ®Google Scholar
• Scharpfenecker M, Fiedler U, Reiss Y, Augustin H G. The Tie-2 ligant angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J Cell Sci 2005; 118: 771–780
   PubMed Web of Science ®Google Scholar
• Uneda S, Matsuno F, Sonoki T, Tniguchi I, Kawano F, Hata H. Expression of vascular endothelial factor and angiopoietin-2 in myeloma cells. Haematologica 2003; 88: 113–115
   PubMed Web of Science ®Google Scholar
• Giuliani N, Colla S, Lazzaretti M, Sala R, Roti G, Mancini C, et al. Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis. Blood 2003; 102: 638–645
   PubMed Web of Science ®Google Scholar
• Nakayama T, Yao L, Tosato C. Mast cell-derived angiopoietin-1 plays a critical role in the growth of plasma cell tumors. J Clin Invest 2004; 114: 1317–1325
   PubMed Web of Science ®Google Scholar
• Quartarone E, Alonci A, Allegra A, Bellomo G, Calabro L, D' Angelo A, et al. Differential levels of soluble angiopoietin-2 and Tie-2 in patients with haematological malignancies. Eur J Haematol 2006; 77: 480–485
   PubMed Web of Science ®Google Scholar
• Dimopoulos M A, Anargyrou K, Katodritou E, Kastritis E, Pouli A, Michali E, et al. The ratio of angiopoietin-1 to angiopoietin 2 is reduced and predicts independently for survival in newly diagnosed patients with multiple myeloma. Blood 2007; 110, abstract 493
   PubMed Web of Science ®Google Scholar
• Anagnostopoulos A, Eleftherakis-Papaiakovou V, Zervas K, Kastritis E, Tsionos K, Bamias A, et al. Serum concentrations of angiogenic cytokines in Waldenstrom's Macroglobulinaemia: the ratio of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity. Br J Haematol 2007; 137: 560–568
   PubMed Web of Science ®Google Scholar
• Anargyrou K, Terpos E, Vassilakopoulos T P, Pouli A, Sachanas S, Tzenou T, et al. Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib. Haematologica in press
   Google Scholar
• Tello-Montoliu A, Patel J V, Lip G Y. Angiogenin: a review of the pathophysiology and potential clinical applications. J Thromb Haemost 2006; 4: 1864–1874
   PubMed Web of Science ®Google Scholar
• Alexandrakis M G, Passam F H, Pappa C A, Sfiridaki K, Tsirakis G, Damilakis J, et al. Relation between bone marrow angiogenesis and serum levels of angiogenin in patients with myelodysplastic syndromes. Leuk Res 2005; 29: 41–46
   PubMed Web of Science ®Google Scholar
• Alexandrakis M G, Passam F H, Sfiridaki A, Kyriakou D S, Petreli E, Roussou P. Elevated serum angiogenin in multiple myeloma. Hematol J 2003; 4: 454–455
   PubMedGoogle Scholar
• Derksen P W, Keehnen R M, Evers L M, van Oers M H, Spaargaren M, Pals S T. Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood 2002; 99: 1405–1410
   PubMed Web of Science ®Google Scholar
• Andersen N F, Standal T, Nielsen J L, Heickendorff L, Borset M, Sorensen F B, et al. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival. Br J Haematol 2005; 128: 210–217
   PubMed Web of Science ®Google Scholar
• Bisping G, Leo R, Wenning D, Dankbar B, Padro T, Kropff M, et al. Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma. Blood 2003; 101: 2775–2783
   PubMed Web of Science ®Google Scholar
• Sezer O, Jakob C, Eucker J, Niemoller K, Gatz F, Wernecke K, et al. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. Eur J Haematol 2001; 66: 83–88
   PubMed Web of Science ®Google Scholar
• Hirama M, Takahashi F, Takahashi K, Akutagawa S, Shimizu K, Soma S, et al. Osteopontin overproduced by tumor cells act as a potent angiogenic factor contributing to tumor growth. Cancer Lett 2003; 198: 107–117
   PubMed Web of Science ®Google Scholar
• Colla S, Morandi F, Lazzaretti M, Rizzato R, Lunghi P, Bonomini S, et al. Human myeloma cells express the bone regulating gene Runx2/Cbfa1 and produce osteopontin that is involved in angiogenesis in multiple myeloma patients. Leukemia 2005; 19: 2166–2176
   PubMed Web of Science ®Google Scholar
• Terpos E, Mihou D, Szydlo R, Tsimirika K, Karkantaris C, Politou M, et al. The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. Leukemia 2005; 19: 1969–1976
   PubMed Web of Science ®Google Scholar
• Martin S K, Dewar A L, Farrugia A N, Horvath N, Gronthos S, To L B, et al. Tumor angiogenesis is associated with plasma levels of stromal-derived factor-1-alpha in patients with multiple myeloma. Clin Cancer Res 2006; 12: 6973–6977
   PubMed Web of Science ®Google Scholar
• Hayashi T, Hideshima T, Nguyen A N, Munoz O, Podar K, Hamasaki M, et al. Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin Cancer Res 2004; 10: 7540–7546
   PubMed Web of Science ®Google Scholar
• Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson K C. The role of tumor necrosis factor-alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 2001; 20: 4519–4527
   PubMed Web of Science ®Google Scholar
• Terpos E, Politou M, Viniou N, Rahemtulla A. Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma. Leuk Lymphoma 2005; 46: 1699–1707
   PubMed Web of Science ®Google Scholar
• Vacca A, Ribatti T, Presta M, Minischetti M, Iurlaro M, Ria R, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999; 93: 3064–3073
   PubMed Web of Science ®Google Scholar
• Vande Broek I, Asosingh K, Allegaert V, Leleu X, Facon T, Vandrkerken K, et al. Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: evidence for a role of hepatocyte growth factor. Leukemia 2004; 18: 976–982
   PubMed Web of Science ®Google Scholar
• Murdoch C, Giannoudis A, Lewis C E. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 2004; 104: 2224–2234
   PubMed Web of Science ®Google Scholar
• Bingle L, Brown N J, Lewis C E. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002; 196: 254–265
   PubMed Web of Science ®Google Scholar
• Leek R D, Lewis C E, Whitehouse R, Greenall M, Clarke J, Harris A L. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 1996; 56: 4625–4629
   PubMed Web of Science ®Google Scholar
• De Palma M, Venneri M A, Galli R. Tie2 identifies hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005; 8: 211–226
   PubMed Web of Science ®Google Scholar
• Pennathur-Das R, Levitt L. Augmentation of in vitro human marrow erythropoiesis under physiological oxygen tensions is mediated by monocytes and T lymphocytes. Blood 1987; 69: 899–907
   PubMed Web of Science ®Google Scholar
• Asosingh K, De Raeve H, De Ridder M, Storme G A, Willems A, Van Riet I, et al. Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression. Haematologica 2005; 90: 810–817
   PubMed Web of Science ®Google Scholar
• Meininger C J, Zetter B R. Mast cells and angiogenesis. Semin Cancer Biol 1992; 3: 73–79
   PubMedGoogle Scholar
• Gruber B L, Marchese M J, Kew R. Angiogenic factors stimulate mast-cell migration. Blood 1995; 86: 2488–2493
   PubMed Web of Science ®Google Scholar
• Ribatti D, Vacca A, Nico B, Crivellato E, Roncali L, Dammacco F. The role of mast cells in tumour angiogenesis. Br J Haematol 2001; 115: 514–521
   PubMed Web of Science ®Google Scholar
• Ribatti D, Vacca A, Nico B, Quondamatteo F, Ria R, Minischetti M, et al. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. Br J Cancer 1999; 79: 451–455
   PubMed Web of Science ®Google Scholar
• Nakayama T, Yao L, Tosato G. Mast cell-derived angiopoietin-1 plays a critical role in the growth of plasma cell tumors. J Clin Invest 2004; 114: 1317–1325
   PubMed Web of Science ®Google Scholar
• D'Amato R J, Loughnan M S, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082–4085
   PubMed Web of Science ®Google Scholar
• Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565–1571
   PubMed Web of Science ®Google Scholar
• Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, et al. Extented survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492–494
   PubMed Web of Science ®Google Scholar
• Dimopoulos M A, Zervas K, Kouvatseas G, Galani E, Grigoraki V, Kiamouris C, et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 2001; 12: 991–995
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bertola A, Musto P, Caravita T, Callea V, Nunzi M, et al. Oral melphalan, prednizone and thalidomide for newly diagnosed patients with myeloma. Cancer 2005; 104: 1428–1433
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades C S, Poulaki V, Chauhan D, Richardson P G, Hideshima T, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002; 99: 4525–4530
   PubMed Web of Science ®Google Scholar
• Davies F E, Raje N, Hideshima T, Lentzsch S, Young G, Tai Y T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98: 210–216
   PubMed Web of Science ®Google Scholar
• Yaccoby S, Johnson C L, Mahaffey S C, Wezeman M J, Barlogie B, Epstein J. Antimyeloma efficacy of thalidomide in the SCID-hu model. Blood 2002; 100: 4162–4168
   PubMed Web of Science ®Google Scholar
• Fujita J, Mestre J R, Zeldis J B, Subbaramaiah K, Dannenberg A J. Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2. Clin Cancer Res 2001; 7: 3349–3355
   PubMed Web of Science ®Google Scholar
• Vacca A, Scavelli C, Montefusco V, Di Pietro G, Neri A, Mattioli M, et al. Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J Clin Oncol 2005; 23: 5334–5346
   PubMed Web of Science ®Google Scholar
• Neben K, Moehler T, Kraemer A, Benner A, Egerer G, Ho A D, et al. Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. Br J Haematol 2001; 115: 605–608
   PubMed Web of Science ®Google Scholar
• Dmoszynsca A, Bojarska-Junak A, Domanski D, Rolinski J, Hus M, Soroka-Wojtaszko M. Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma. Leuk Lymph 2002; 43: 401–406
   PubMed Web of Science ®Google Scholar
• Kumar S, Witzig T E, Dispenzieri A, Lacy M Q, Wellik L E, Fonseca R, et al. Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. Leukemia 2004; 18: 624–627
   PubMed Web of Science ®Google Scholar
• Du W, Hattori Y, Hashiguchi A, Kondoh K, Hozumi N, Ikeda Y, et al. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment. Pathol Int 2004; 54: 285–294
   PubMed Web of Science ®Google Scholar
• Hatjiharissi E, Terpos E, Papaioannou M, Hatjileontis C, Kaloutsi V, Galaktidou G, et al. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma. Hematol Oncol 2004; 22: 159–168
   PubMed Web of Science ®Google Scholar
• Mileshkin L, Honemann D, Gambell P, Trivett M, Hayakawa Y, Smyth M, et al. Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines, angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome. Haematologica 2007; 92: 1075–1082
   PubMed Web of Science ®Google Scholar
• Rajkumar S V, Hayman S R, Lacy M Q, Dispenzieri A, Geyer S M, Kabat B, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005; 106: 4050–4053
   PubMed Web of Science ®Google Scholar
• Richardson P G, Blood E, Mitsiades C S, Jagannath S, Zeldenrust S, Alsina M, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006; 108: 3458–3464
   PubMed Web of Science ®Google Scholar
• Kastritis E, Dimopoulos M A. The evolving role of lenalidomide in the treatment of hematologic malignancies. Expert Opin Pharmacother 2007; 8: 497–509
   PubMed Web of Science ®Google Scholar
• Lentzsch S, LeBlanc R, Podar K, Davies F, Lin B, Hideshima T, et al. Immunomodulatory analogs of thalidomide inhibit growth of HS Sultan cells and angiogenesis in vivo. Leukemia 2003; 17: 41–44
   PubMed Web of Science ®Google Scholar
• Dredge K, Marriott J B, Macdonald C D, Man H-W, Chen R, Muller G W, et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 2002; 87: 1166–1172
   PubMed Web of Science ®Google Scholar
• Dredge K, Horsfall R, Robinson S P, Zhang L H, Lu L, Tang Y, et al. Orally administered lenalidomide (CC-5013) is antiangiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 2005; 69: 56–63
   PubMed Web of Science ®Google Scholar
• Richardson P G, Sonneveld P, Schuster M W, Irwin D, Stadmauer E A, Facon T, et al. Bortezomib or high dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487–2498
   PubMed Web of Science ®Google Scholar
• Rosinol L, Oriol A, Mateos M V, Sureda A, Garcia-Sanchez P, Gutierrez N, et al. Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics. J Clin Oncol 2007; 25: 4452–4458
   PubMed Web of Science ®Google Scholar
• Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 2007; 138: 176–185
   PubMed Web of Science ®Google Scholar
• Almond J B, Cohen G M. The proteasome: a novel target for cancer chemotherapy. Leukemia 2002; 16: 433–443
   PubMed Web of Science ®Google Scholar
• Goldberg A L, Rock K. Not just research tools: proteasome inhibitors offer therapeutic promise. Nat Med 2002; 8: 338–340
   PubMed Web of Science ®Google Scholar
• Hideshima T, Chauhan D, Hayashi T, Akiyama M, Mitsiades N, Mitsiades C, et al. Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene 2003; 22: 8386–8393
   PubMed Web of Science ®Google Scholar
• Shono T, Ono M, Izumi H, Jimi S I, Matsushima K, Okamato T, et al. Involvement of the transcription factor NF-κB in tubular morphogenesis of human microvascular endothelial cells by oxidative stress. Mol Cell Biol 1996; 16: 4231–4239
   PubMed Web of Science ®Google Scholar
• Scatena M, Almeida M, Chaisson M L, Fausto N, Nicosia R F, Giachelli C M. NF-κB mediates avβ3 indegrin-induced endothelial cell survival. J Cell Biol 1998; 141: 1083–1093
   PubMed Web of Science ®Google Scholar
• Karl E, Warner K, Zeitlin B, Kaneko T, Wurtzel L, Jin T, et al. Bcl-2 acts in a proangiogenic signaling pathway through nuclear factor-κB and CXC chemokines. Cancer Res 2005; 65: 5063–5069
   PubMed Web of Science ®Google Scholar
• Oikawa T, Sasaki T, Nakamura M, Shimamura M, Tanahashi N, Omra S, et al. The proteasome is involved in angiogenesis. Biochem Biophys Res Commun 1998; 8: 243–248
   Web of Science ®Google Scholar
• Drexler H CA, Risau W, Konerding M A. Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEB J 2000; 14: 65–77
   PubMed Web of Science ®Google Scholar
• Roccaro A M, Hideshima T, Raje N, Kumar S, Ishitsuka K, Yashui H, et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 2006; 66: 184–191
   PubMed Web of Science ®Google Scholar
• LeBlanc R, Catley L P, Hideshima T, Lentzsch S, Mitsiades C S, Mitsiades N, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002; 62: 4996–5000
   PubMed Web of Science ®Google Scholar
• Politou M, Naresh K, Terpos E, Crawley D, Lampert I, Apperley J F, et al. Anti-angiogenic effect of bortezomib in patients with multiple myeloma. Acta Haematol 2005; 114: 170–173
   PubMed Web of Science ®Google Scholar
• Presta L G, Chen H, O' Connor S J, Chisholm V, Meng Y G, Krummen L, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57: 4593–4599
   PubMed Web of Science ®Google Scholar
• Lin Y S, Nguyen C, Mendoza J L, Escandon E, Fei D, Meng Y G, et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 1999; 288: 371–378
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry M C, Brahmer J, Schiller J H, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542–2550
   PubMed Web of Science ®Google Scholar
• Yang J C, Haworth L, Sherry R M, Hwu P, Shcwartzentruber D J, Topalian S L, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427–434
   PubMed Web of Science ®Google Scholar
• Fong T A, Shawver L K, Sun L, Tang C, App H, Powell T J, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999; 59: 99–106
   PubMed Web of Science ®Google Scholar
• Zangari M, Anaissie E, Stopeck A, Morimoto A, Tan N, Lancet J, et al. Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin Cancer Res 2004; 10: 3365–3370
   PubMed Web of Science ®Google Scholar
• Wood J M, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, et al. PTK787/ZK222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000; 60: 2178–2189
   PubMed Web of Science ®Google Scholar
• Lin B, Podar K, Gupta D, Tai Y T, Li S, Weller E, et al. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK 787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res 2002; 62: 5019–5026
   PubMed Web of Science ®Google Scholar
• Wilhelm S M, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 excibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099–7109
   PubMed Web of Science ®Google Scholar
• O'Farrell A M, Abrams T J, Yuen H A, Nqai T J, Louie S G, Yee K W, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101: 3597–3605
   PubMed Web of Science ®Google Scholar
• Mendel D B, Laird A D, Xin X, Louie S G, Christensen J G, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327–337
   PubMed Web of Science ®Google Scholar
• Wedge S R, Ogilvie D J, Dukes M, Kendrew J, Chester R, Jackson J A, et al. ZD6474 inhibits vascular endothelial growth factor signalling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002; 62: 4646–4655
   Google Scholar
• Kovacs M J, Reece D E, Marcellus D, Meyer R M, Mathews S, Dong R P, et al. A phase II study of ZD6474 (Zactima, a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma—NCIC CTG IND.145. Invest New Drugs 2006; 24: 529–535
   PubMed Web of Science ®Google Scholar
• Sorbera L A, Bolos J, Serradell N. Pazopanib hydrochloride. Drugs Future 2006; 31: 585–589
   Web of Science ®Google Scholar
• Podar K, Tonon G, Sattler M, Tai Y T, LeGouill S, Yasui H, et al. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci USA 2006; 103: 19478–19483
   PubMed Web of Science ®Google Scholar
• Prince H M, Hönemann D, Spencer A, Rizzieri D, Stadtmauer E A, Roberts A, et al. VEGF-R inhibition with pazopanib (GW786034) is ineffective in pretreated myeloma. Haematologica 2007; 92: s2, PO-602
   Google Scholar
• Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2: 727–739
   PubMed Web of Science ®Google Scholar
• Podar K, Anderson K C. Inhibition of VEGF signalling pathways in multiple myeloma and other malignancies. Cell Cycle 2007; 6: 538–542
   PubMed Web of Science ®Google Scholar
• Browder T, Butterfield C E, Kraling B M, Shi B, Marshall B, O'Reilly M S, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug resistant cancer. Cancer Res 2000; 60: 1878–1886
   PubMed Web of Science ®Google Scholar
• Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin D J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000; 105: R15–R24
   PubMed Web of Science ®Google Scholar
• Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000; 105: 1045–1047
   PubMed Web of Science ®Google Scholar
• Morabito A, DeMaio E, DiMaio M, Normanno N, Perrone F. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist 2006; 11: 753–764
   PubMed Web of Science ®Google Scholar